Finding ways to reduce side effects from prostate cancer radiation treatment using genetics.
Official title: Reducing toxicity from prostate cancer radiotherapy through genetics and technology
Funded at University of California Los Angeles · NIH-10945982 · Data updated 2026-11-12
This study is looking at how certain genes might help doctors figure out which men with localized prostate cancer could have tough side effects from radiation therapy, so they can tailor treatments to make things easier for them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $360,281 |
| NIH project number | 1R37CA292795-01 |
| Project ID | NIH-10945982 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are prostate cancer patients undergoing radiation therapy who are interested in understanding their genetic predisposition to treatment-related side effects.
✕Less likely to help
Patients who are not undergoing radiation therapy for prostate cancer or those with advanced metastatic disease may not benefit from this research.
What this research studies
This research aims to identify genetic markers that can help predict which prostate cancer patients are likely to experience severe side effects from radiation therapy. By analyzing specific genetic variations, known as single nucleotide polymorphisms (SNPs), the study seeks to personalize treatment plans and minimize adverse effects. The approach involves collecting genetic data from patients and correlating it with their responses to radiation therapy, ultimately improving patient quality of life. This research is particularly focused on localized prostate cancer, a common condition treated with radiation.
Why it matters
Potential benefit: If successful, this research could lead to more personalized radiation treatments that reduce harmful side effects for prostate cancer patients.
How similar studies have gone: Previous research has shown promise in identifying genetic markers for treatment toxicity in other cancers, suggesting that this approach may yield valuable insights for prostate cancer as well.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Kishan, Amar U — University of California Los Angeles
- Study coordinator: Kishan, Amar U
Related research
Other NIH-funded projects on the same topics.
-
Reducing prostate cancer radiotherapy toxicity through genes and technology
A study to find genetic clues that predict who will have side effects from prostate cancer radiotherapy and to use new tools to reduce those risks.
-
MRI and blood tests to predict prostate cancer outcomes after radiation
This project uses repeated MRI scans and blood-based tumor markers to find early signs that predict how men with intermediate or high-risk prostate cancer do after radiation and hormone therapy.
-
Tiny urine particles that may signal or cause bladder damage after prostate cancer radiation
Researchers will look at small particles in urine and blood to find markers or mechanisms of bladder damage in men treated with radiation for prostate cancer.
-
Investigating imaging and blood markers to improve prostate cancer treatment outcomes
This study is looking to help men with intermediate and high-risk prostate cancer who are getting radiation treatment by finding early signs that show how well the treatment is working, using special imaging and blood tests, so doctors can make better decisions about their care.
-
Making prostate cancer radiation treatment safer using genetics
This work aims to discover genetic markers that can help predict which prostate cancer patients might experience side effects from radiation therapy, allowing for more personalized care.
-
Investigating how tiny particles affect bladder toxicity in prostate cancer patients after radiation treatment
This study is looking at tiny particles in the body called extracellular vesicles to see if they can help predict bladder problems in prostate cancer patients who have had radiation treatment, with the goal of finding better ways to manage these issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.